This budget may double in the case of NSCLC analysis, because lung carcinomas have to be additionally tested for EGFR, BRAF, KRAS, MET, and HER2 mutations as well as ALK, ROS1, and RET translocations [17,18,46,47]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.